Solid Biosciences Provides Third Quarter 2022 Business Update and Financial Results
10. November 2022 07:34 ET
|
Solid Biosciences Inc.
- Recently presented preclinical data support potential benefits of next-generation Duchenne gene therapy candidate SGT-003; program on track for mid-2023 Investigational New Drug (IND) submission - ...
Solid Biosciences Announces a 1-for-15 Reverse Stock Split
27. Oktober 2022 08:00 ET
|
Solid Biosciences Inc.
- Effective at 5 pm ET October 27, 2022 - CHARLESTOWN, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful...
Solid Biosciences Reports Additional Preclinical Data Demonstrating that its Novel Capsid, AAV-SLB101, Provides Superior Transduction Efficiency and Enhanced Distribution to Skeletal Muscle
17. Oktober 2022 08:00 ET
|
Solid Biosciences Inc.
- AAV-SLB101 is the capsid used in SGT-003, Solid’s next-generation Duchenne gene therapy, expected to enter the clinic in late-2023 - - Additional novel capsids based on AAV-SLB101 binding...
Solid Biosciences Presents New SGT-001 IGNITE DMD Study Results at World Muscle Society 2022 Congress Demonstrating Improvements in Ambulatory Function
13. Oktober 2022 08:00 ET
|
Solid Biosciences Inc.
- Stride velocity 95th centile (SV95C) data demonstrate improvements at one-year post-dosing compared with declines observed in control and natural history patients - - SV95C is an objective,...
Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement
30. September 2022 07:00 ET
|
Solid Biosciences Inc.
- Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases, led by industry veteran and current AavantiBio CEO, Bo Cumbo - - Strong...
Solid Biosciences to Participate at Upcoming Investor Conferences
29. September 2022 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Provides Second Quarter 2022 Business Update and Financial Results
11. August 2022 07:53 ET
|
Solid Biosciences Inc.
- Transition to transient transfection-based manufacturing process continues for SGT-001; Company expects to continue dosing patients in 2023 - - Development of next-generation Duchenne gene therapy...
Solid Biosciences to Present at Upcoming Scientific and Patient Advocacy Conferences
23. Juni 2022 08:00 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Quality
02. Juni 2022 08:30 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences to Participate at the Jefferies Healthcare Conference
02. Juni 2022 08:00 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...